RxDoctor Payments Data

Neil Rennick, DO

Family Medicine · East Troy, WINPI 1508062043

Payments from drug & device makers

$1,120in general payments, 2019–2025

Across 46 payments — averaging $24.34 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$303
  • Boehringer Ingelheim$252
  • Lilly USA, LLC$225
  • Pfizer$193
  • Biohaven Pharmaceuticals, Inc.$126
  • Biohaven Pharmaceutical Holding Company Ltd.$22

What the payments were for

  • Food & beverage$1,10599%
  • Education$151%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,120 in reported general payments places this provider in the 85th percentile of 1,482 family medicine providers in Wisconsin.

See all family medicine providers in Wisconsin

Medicare billing

Part B allowed, 2024
$50,249
Medicare patients
46
Services billed
475

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide55$71,892
JardianceEmpagliflozin51$60,401
MounjaroTirzepatide40$56,582
TrulicityDulaglutide22$43,642
EliquisApixaban16$19,665
TradjentaLinagliptin16$12,468
Colchicine80$8,634
ShingrixVaricella-Zoster Ge/As01b/Pf17$3,561
Levothyroxine Sodium143$1,669
Omeprazole46$1,189
Rosuvastatin Calcium126$1,093
Ezetimibe25$1,037
Leflunomide29$962
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen14$863
Atorvastatin Calcium60$728

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$225$100,22462 claims
Boehringer IngelheimJardiance, Tradjenta$252$72,86967 claims
Novo NordiskOzempic$303$71,89255 claims
PfizerEliquis$193$19,66516 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,482 family medicine providers in Wisconsin.

Other family medicine in East Troy

See the full list for Wisconsin

Where these figures come from

Is this you, or does something look wrong? →